Matches in SemOpenAlex for { <https://semopenalex.org/work/W2035546945> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2035546945 abstract "Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FLCancer growth in the brain incites a neuroinflammatory response that becomes a defining feature of the brain tumor microenvironment. Microglia and macrophages provide important functions that support the invasiveness of glioblastoma. Other cancer types that become metastatic to brain also rely on the microenvironment to support angiogenesis.PLX3397 is a potent inhibitor of the transmembrane tyrosine kinase receptor for colony stimulating factor-1 (CSF-1R). The CSF-1R is required for the differentiation and activation of microglia and macrophages. Oral administration of PLX3397 to mice at 20 mg/kg qd significantly reduces the microglia/macrophage marker, Iba1, as determined by western blotting.PLX3397 penetrates the blood-brain barrier, as determined through pharmacokinetic analysis, with brain levels reaching substantial fractions of the concurrent plasma levels. PLX3397 is highly bound to plasma albumin, and therefore the levels attained in the brain likely affect Iba1 levels through a local inhibition of brain microglia and macrophages, although a peripheral effect may also contribute.Culture of glioblastoma cell lines including U87, and treatment with chemotherapeutic agents or radiation, was found to cause a 4-fold elevation of the two CSF-1R ligands, CSF-1 and IL-34, as quantified by QPCR. This indicates that glioma cells can recruit and stimulate microglia and macrophages, and that current standard therapies likely exacerbate this stimulation. Other cancer types that are known to form metastases to brain, including melanoma and breast cancer, show similar abilities to produce these cytokines in response to standard therapies.The rat 9L glioblastoma line forms an aggressive tumor when tested as an orthotopic model in syngeneic Fisher rats. Seven days after implantation, PLX3397 was administered via rodent chow for 14 days, reducing the tumor growth by 44% as determined by MRI.These results provide preclinical evidence that PLX3397 may show a clinical benefit in brain cancers, either as a single agent or in combination with standard chemo- or radiation therapies. PLX3397 is nearing completion of a successful Phase 1 dose-escalation safety trial in solid tumor cancer patients.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 552. doi:10.1158/1538-7445.AM2011-552" @default.
- W2035546945 created "2016-06-24" @default.
- W2035546945 creator A5012421943 @default.
- W2035546945 creator A5038082959 @default.
- W2035546945 creator A5046923558 @default.
- W2035546945 creator A5049323646 @default.
- W2035546945 creator A5059061474 @default.
- W2035546945 creator A5069230508 @default.
- W2035546945 creator A5079252287 @default.
- W2035546945 creator A5085858912 @default.
- W2035546945 creator A5090555697 @default.
- W2035546945 date "2011-04-15" @default.
- W2035546945 modified "2023-10-15" @default.
- W2035546945 title "Abstract 552: Targeting brain tumors with PLX3397, an inhibitor of the CSF-1 receptor kinase" @default.
- W2035546945 doi "https://doi.org/10.1158/1538-7445.am2011-552" @default.
- W2035546945 hasPublicationYear "2011" @default.
- W2035546945 type Work @default.
- W2035546945 sameAs 2035546945 @default.
- W2035546945 citedByCount "0" @default.
- W2035546945 crossrefType "proceedings-article" @default.
- W2035546945 hasAuthorship W2035546945A5012421943 @default.
- W2035546945 hasAuthorship W2035546945A5038082959 @default.
- W2035546945 hasAuthorship W2035546945A5046923558 @default.
- W2035546945 hasAuthorship W2035546945A5049323646 @default.
- W2035546945 hasAuthorship W2035546945A5059061474 @default.
- W2035546945 hasAuthorship W2035546945A5069230508 @default.
- W2035546945 hasAuthorship W2035546945A5079252287 @default.
- W2035546945 hasAuthorship W2035546945A5085858912 @default.
- W2035546945 hasAuthorship W2035546945A5090555697 @default.
- W2035546945 hasConcept C121608353 @default.
- W2035546945 hasConcept C126322002 @default.
- W2035546945 hasConcept C142724271 @default.
- W2035546945 hasConcept C170493617 @default.
- W2035546945 hasConcept C185592680 @default.
- W2035546945 hasConcept C2776107976 @default.
- W2035546945 hasConcept C2776914184 @default.
- W2035546945 hasConcept C2778227246 @default.
- W2035546945 hasConcept C2779130545 @default.
- W2035546945 hasConcept C2779830541 @default.
- W2035546945 hasConcept C502942594 @default.
- W2035546945 hasConcept C71924100 @default.
- W2035546945 hasConcept C96232424 @default.
- W2035546945 hasConceptScore W2035546945C121608353 @default.
- W2035546945 hasConceptScore W2035546945C126322002 @default.
- W2035546945 hasConceptScore W2035546945C142724271 @default.
- W2035546945 hasConceptScore W2035546945C170493617 @default.
- W2035546945 hasConceptScore W2035546945C185592680 @default.
- W2035546945 hasConceptScore W2035546945C2776107976 @default.
- W2035546945 hasConceptScore W2035546945C2776914184 @default.
- W2035546945 hasConceptScore W2035546945C2778227246 @default.
- W2035546945 hasConceptScore W2035546945C2779130545 @default.
- W2035546945 hasConceptScore W2035546945C2779830541 @default.
- W2035546945 hasConceptScore W2035546945C502942594 @default.
- W2035546945 hasConceptScore W2035546945C71924100 @default.
- W2035546945 hasConceptScore W2035546945C96232424 @default.
- W2035546945 hasLocation W20355469451 @default.
- W2035546945 hasOpenAccess W2035546945 @default.
- W2035546945 hasPrimaryLocation W20355469451 @default.
- W2035546945 hasRelatedWork W2000200224 @default.
- W2035546945 hasRelatedWork W2023557044 @default.
- W2035546945 hasRelatedWork W2045420985 @default.
- W2035546945 hasRelatedWork W2058736371 @default.
- W2035546945 hasRelatedWork W2069898686 @default.
- W2035546945 hasRelatedWork W2073292483 @default.
- W2035546945 hasRelatedWork W2086159802 @default.
- W2035546945 hasRelatedWork W2133703191 @default.
- W2035546945 hasRelatedWork W2267102674 @default.
- W2035546945 hasRelatedWork W2329754083 @default.
- W2035546945 hasRelatedWork W2332479714 @default.
- W2035546945 hasRelatedWork W2532592435 @default.
- W2035546945 hasRelatedWork W2620846290 @default.
- W2035546945 hasRelatedWork W2810730266 @default.
- W2035546945 hasRelatedWork W2914640112 @default.
- W2035546945 hasRelatedWork W2987564536 @default.
- W2035546945 hasRelatedWork W2996311212 @default.
- W2035546945 hasRelatedWork W3082773264 @default.
- W2035546945 hasRelatedWork W3164389686 @default.
- W2035546945 hasRelatedWork W2143177304 @default.
- W2035546945 isParatext "false" @default.
- W2035546945 isRetracted "false" @default.
- W2035546945 magId "2035546945" @default.
- W2035546945 workType "article" @default.